What happened
Lunit will present five abstracts at ESMO 2026 (Madrid, Oct 23–27) using its Lunit Scope platform, including first results from AIforHER, a breast cancer AI project led by France's ICO with AstraZeneca and Daiichi Sankyo, and was selected for a two-company follow-up study.
Why it matters
Being chosen for the follow-up study suggests Lunit's AI is among the tools drugmakers and research institutions are testing to distinguish subtle HER2 expression differences, which matter as ultra-low HER2 patients become eligible for ADC therapy, according to the company.
WHO IT HITSPharma R&D teams and pathologists working on HER2-low breast cancer and other biomarker-defined cancers may see new AI-assisted ways to classify patients for targeted therapy, though clinical validation is still underway.
Summaries like this, in your inbox every morning.
Lunit's ESMO 2026 lineup centers on the first results from AIforHER, a project led by France's ICO with AstraZeneca and Daiichi Sankyo that develops and validates AI algorithms for personalized breast cancer treatment. The project compared multiple companies' AI solutions for patients with very low HER2 protein expression, a distinction that has become important as such "HER2 ultra-low" patients become eligible for ADC therapy.
Beyond breast cancer, Lunit will present a lung cancer study comparing pathologist and AI assessment of PD-L1, and a pancreatic cancer study analyzing how stroma and genetic mutations relate to prognosis. The company said it was selected for a two-company follow-up study to validate its solution in real clinical settings. CEO Seo Beom-seok said the research examines AI's role in areas where microscope reading alone is difficult to judge.
Pick your industry and the AI tools you use, and get news related to your work every day.
Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.
LSTC, Hokkaido University and Fujifilm said they will jointly develop an AI medical image-processing system, w…
OpenAI Group PBC acquired drug development software startup Orchestra Bio Inc., whose AI agents monitor studie…
Wells Fargo executive Faraz Shafiq said the $2.3 trillion-asset bank aims to use AI to "fundamentally transfor…
IBM, Red Hat and Google released llm-d version 1.0, adding multi-tenant quality of service, zero-downtime oper…
Pelican AI hired Maria Papas as VP of Sales, Americas, and Doug Drummond as Head of Channels and Alliances to…
AstraZeneca has partnered with Oracle to apply AI to its clinical trials, Reuters reported
